A credit to Dr.Cauwenbergh's mgmt, in his own words he continues to advance RXI (quote),
"on time and on budget"........................GL
MARLBOROUGH, Mass., July 30, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that their third Phase 2a study (RXI-109-1402) with RXI-109, for the reduction of recurrence of hypertrophic scars following elective scar revision surgery, has been initiated."
If memory serves me, Dr. Couwenbergh did mention that a third ph2 study would commence when they had a good indication from the first two studies. Unless this new study is simply a similar study of the first two for further validation? Not sure. GLTA
My point exactly. It appears the goal is to aggressively, (as best they can with a mere staff of twelve at the moment), expand on the pipelines. That is what will evolve this company to a major player. Cauwenbergh's goal no doubt. This is the very reason why I feel the day to day stock price may not be an issue to them at this point in time. I could be wrong, but that's how I see it.
Along with Dr. Frost, Dr. Cauwenbergh also has a long history of creating value in the companies he has headed. I put my money on him...............GL
FDA can be as suspect as they like. It is the trials that will prove or disprove safety, not the FDA. RNAi now on the cutting edge of therapies for most nearly all diseases. Medicine as we know it is about to change. GLTA
"Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics."
Alny target rare diseases, market cap $5.1B. RXI potentially closer to market of either, with proven "self deliery" applicable to any number of RNAi compounds, as well as whole families of RNAi IP yet to be tested and adapted to sd-rxRNA, yet has a market cap of a mere $35M.
Why then so hidden from the radar screen? Can only scratch my head here.
ALNY workin on liver fibrosis, a market potential in the tens on billions. RXI also working on liver fibrosis, and if can deliver systemically, which Cauwenbergh made mention of strong likelihood, may get the attention of the investment community and could rocket RXI's m/cap exponentially.
I,m convinced that mgmt is not at all concerned with near term stock price, as they, along with Dr. Frost who holds a sizable stake in the company, are after bigger game................Just my thought this morning..GLTA
Good find. To conclude the reference to RXI;
"RXi sought space renting for about $15 to $20 a square foot. In Boston and Cambridge, space can rent for $40 to $80 a square foot, according to Mr. Umphrey. Worcester labs tend to rent in the low $20s per square foot, he said."
A multi faceted CEO / CFO .
Good luck All
Impressive. Dr Cauwenbergh surrounds himself with top talent, just as the addition of Dr. Peter Campochiaro last week.
He continues to execute his (quote); "well conceived plan". ................Good luck All
That 113M was pre reverse split. It now equates to just 3.7M shares. Why are you such a jerk avi, attempting to deceive people with half truths and lies? You'll get yours avi.....................
But cannot help but think this little company has not warranted the attention of much of a crowd. Is it possible that so few have noticed RXI's potential?
Skin scarring may not be an attention grabber, thus I suspect few have gone through the trouble of studying the market potential of such a therapy.
All the better for those who have invested this early. If the science proved positive in the next month or two rewards will be handsome IMHO. Just my thought this afternoon, Good luck to All............
Bio, looks like your comment hit the mark with prd747 and avimoron below. A couple of real sophisticates aren't they. GLTA
Nobody in their right mind would short this stock at this price. You are a real Dope avimoron..................
As you know I follow the science and it is obviously the main attraction. Just so happens RXI has on of the best CEO's in the business, IMHO. GLTA
Few falling off perhaps due to impatience and lower pps. RXI fundamentally stronger. Hard to justify lack of buying interest other than the time required to complete p2 and a lack of news.
But those two issues do not concern me, as Dr. C. isn't one to throw out PR very often, as you all know. The complete picture keeps my sentiment very bullish on the company.
He is results driven. Will keep my $ on him. It's why I'm here in the first place........GLTA
why does he keep trying to discredit RXI with half truths and scare tactics? I'll tell you why. Because his bosses are trying to buy shares on the cheap.
Why else would a person who does not like a company post on its message board 10 times per day?
Save your energy avi, everybody knows what you are doing and why you are here...............
Enough cash yes, but must never overlook the fact that a company cannot simply use up all cash and then go scrambling for more.
A cushion of at least one year's estimated burn must always be on hand. RXI is expanding and the burn rate will increase. Although I see no immediate need to raise $ especially with the equity line on hand from LPC, at some point down the road more funding needed. Perhaps partnerships will eliminate that need?
In any case, we are in very good hands. Dr. C. is a perfectly capable CFO, imho